Personalis (NASDAQ:PSNL) Stock Price Down 9.3% – Time to Sell?

Personalis, Inc. (NASDAQ:PSNL)’s stock price fell 9.3% on Friday . The stock traded as low as $6.66 and last traded at $6.6380. 627,854 shares changed hands during trading, a decline of 55% from the average session volume of 1,402,346 shares. The stock had previously closed at $7.32.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PSNL. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Thursday, January 22nd. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Needham & Company LLC lifted their price objective on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Guggenheim boosted their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. Finally, Morgan Stanley dropped their target price on shares of Personalis from $11.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, March 5th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.50.

Personalis Trading Down 11.5%

The company has a market cap of $677.49 million, a price-to-earnings ratio of -7.12 and a beta of 2.02. The business’s 50 day moving average price is $8.54 and its 200-day moving average price is $8.34.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.05. The business had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 39.13%. Equities research analysts forecast that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Institutional Trading of Personalis

Institutional investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its holdings in Personalis by 76.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Personalis during the second quarter worth $30,000. International Assets Investment Management LLC bought a new stake in shares of Personalis in the fourth quarter valued at about $31,000. Ameritas Investment Partners Inc. bought a new stake in shares of Personalis in the second quarter valued at about $34,000. Finally, BNP Paribas Financial Markets grew its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after acquiring an additional 5,177 shares in the last quarter. 61.91% of the stock is currently owned by institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.